Medical treatment of recurrent ischaemic priapism: a review of current molecular therapeutics and a new clinical management paradigm

Gregory A. Joice, James L. Liu, Arthur L. Burnett

Research output: Contribution to journalReview articlepeer-review

Abstract

Objectives: To examine the current molecular therapeutics in the medical treatment of recurrent ischemic priapism (RIP). To propose a stepwise clinical management paradigm for the treatment of RIP. Methods: We performed a literature search using the PubMed database for the terms ‘recurrent ischemic priapism’ and ‘stuttering priapism’ up until December 2020. We assessed pre-clinical and clinical studies regarding medical management of RIP and molecular pathophysiology. Case series and randomized trials were evaluated by study quality and patient outcomes to determine a potential clinical management scheme. Results: Recent research has fostered an improved understanding of the underlying molecular pathophysiology of RIP that has paved the way forward for developing new therapeutic agents. Medications targeting neurovascular, hormonal and haematological mechanisms associated with RIP show great promise towards remedying this condition. A host of therapeutic agents operating across different mechanistic directions may be implemented according to a clinical management scheme to potentially optimize RIP outcomes. Conclusion: RIP remains a medically neglected condition with current management focused on treating the acute condition rather than modulating the course of disease. Continued research into the molecular mechanisms of RIP and standardized clinical pathways can improve the quality of care for patients suffering from this condition.

Original languageEnglish (US)
JournalBJU International
DOIs
StateAccepted/In press - 2021

Keywords

  • #Priapism
  • erectile dysfunction
  • molecular therapy
  • penile erection
  • penis
  • sickle cell disease

ASJC Scopus subject areas

  • Urology

Fingerprint Dive into the research topics of 'Medical treatment of recurrent ischaemic priapism: a review of current molecular therapeutics and a new clinical management paradigm'. Together they form a unique fingerprint.

Cite this